Artesunate versus quinine in the treatment of severe falciparum malaria
in African children (AQUAMAT): An open-label, randomised trial.
Leucopenia (below 4000/ [micro]L) was observed in only 8 (11.4%) cases and leucocytosis (above 11,000/[micro]L) was seen in 4 patients (5.7%) out of the total 70 cases, all 4 were suffering from falciparum malaria
. This study did not show significant statistical difference in total leucocyte count between these two species (p-value > 0.05) [Table 3].
Predicting the clinical outcome of severe falciparum malaria
in african children: Findings from a large randomized trial.
Clinical profile of Falciparum malaria
in a tertiary care hospital.
Evidence of Plasmodium falciparum malaria
multidrug resistance to artemisinin and piperaquine in western Cambodia: dihydroartemisinin-piperaquine open-label multicenter clinical assessment.
in children and adult patients in Cote d'Ivoire.
Development and testing of LAMP assay for diagnosis of Plasmodium falciparum malaria
. Ethinicity and Disease., 2009; 19:23-24.
At the time of those studies, mefloquine was the treatment of choice for uncomplicated multiresistant falciparum malaria
. A standard dose of 15 mg/kg of mefloquine became ineffective in treating acute falciparum malaria
in an area with deteriorating multidrug resistance on the Thai-Myanmar border.
This study investigated the effect of age on the concentration of mefloquine in the plasma and erythrocytes of patients with uncomplicated falciparum malaria
in the Amazon basin.
A study conducted by Qurban et al, reported 93.33% of thrombocytopenia in patients having Plasmodium vivax.15 In contrast to our study Jadhav and Patkar conducted an extensive study regarding pattern of thrombocytopenia in patients having vivax and falciparum malaria
. They documented thrombocytopenia in both groups of patients but severe thrombocytopenia, (platelets 20,000 or less) was more consistent with Plasmodium falciparum malaria
, while Memon has reported thrombocytopenia in malaria to be about 70%.16,17
Comparative efficacies of Artemisinin combination therapies in Plasmodium falciparum malaria
and polymorphism of PfATPase6, pfcrt, pfdhfr and pfdhps genes in tea gardens of Jalpaiguri district.
Over a 2-year period, 1,241 patients aged 6 months to 65 years with acute, uncomplicated falciparum malaria
were randomly assigned to receive either 2 mg or 4 mg of oral artesunate for 3 days, followed by a standard 3-day course of artemisinin-based combination therapy.